| ★ |  Crinecerfont Sustains Glucocorticoid Reduction, Improves Cardiometabolic Outcomes in Classic CAH | | 74 | Estados Unidos | |
| 14 |  Stop the "Ozempic Rebound": The Science of GLP-1 Microdosing | Dr. G's Lifestyle Medicine Network @gooddrg | 8.5K | Estados Unidos | 86 |
| 18 |  My morning ritual changed when I stopped thinking of protein as just a fitness supplement! | Molly Pelletier, MS, RD | The Reflux Dietitian @mollypelletierrd | 7.5K | Estados Unidos | 86 |
| 19 |  Día Mundial de la Hipertensión. Manejo Cardio-Reno-Metabólico en la Atención Primaria de Salud | | 1.4K | Estados Unidos | 86 |
| 11 |  Retatrutide Provides Substantial Weight Loss in Patients With Obesity or Overweight | | 1.1K | Estados Unidos | 86 |
| 17 |  TRATAMIENTO DEL SINDROME DE CUSHING EN PERROS ALIMENTACIÓN CORRECTA | ¿QUE COMEN LOS ANIMALES? @quecomenlosanimales | 920 | España | 86 |
| 6 |  TRIUMPH-2: Retatrutide Reduces Weight, A1C in Patients With Obesity | | 350 | Estados Unidos | 87 |
| 12 |  Diabetes Dialogue: Tech, Screening, and Care Highlights from ADCES 2026 | | 224 | Estados Unidos | 86 |
| 10 |  Diabetes Dialogue: CKM Systems, Triple Agonists, and a Sensor Scandal Ahead of ADA | | 179 | Estados Unidos | 86 |
| 2 |  Night Dose of Hydrocortisone – Smart Choice or Mistake? #aldhope #adrenalinsufficiency #sleep | | 171 | — | 88 |
| 4 |  Retatrutide Cuts Weight, Cardiovascular Disease Risk in TRIUMPH-3 | | 158 | Estados Unidos | 87 |
| 7 |  CALIBRATE: Encaleret Achieves Mineral Homeostasis in Patients With ADH1, With Rachel Gafni, MD | | 88 | Estados Unidos | 87 |
| 8 |  Diabetes Dialogue: Signos and the Science of Weight Loss | | 75 | Estados Unidos | 86 |
| 1 |  Crinecerfont Enables Sustained Glucocorticoid Dose Reductions Through 2 Years in Adults With CAH | | 67 | Estados Unidos | 98 |
| 5 |  هل هناك درجات من التضخم الكظري الخلقي؟ هل يمكن الشفاء منه؟ Q8 | | 56 | — | 87 |
| 20 |  Converting Basal Insulin Patients to Insulin Icodec | | 49 | Estados Unidos | 86 |
| 16 |  CAPTAIN-T2D: Interim Results Display High Cortisol Prevalence in Difficult-to-Control T2D | | 47 | Estados Unidos | 86 |
| 3 |  Continuous Ketone Monitoring May Guide SGLT2i Use in T1D | | 33 | Estados Unidos | 87 |
| 9 |  Día Mundial de la Obesidad | Líderes en Nutrición @lideresennutricion | 26 | México | 86 |
| 13 |  Ersodetug Shows Target Engagement but Misses Primary Endpoints in Phase 3 cHI Study | | 20 | Estados Unidos | 86 |
| 15 |  Adrenal Steroids & Related Drugs | Chapter 33 – Brenner & Stevens’ Pharmacology (6th) | Last Minute Lecture @lastminutelecture | 13 | Estados Unidos | 86 |